BioNTech's 18.5-Month Survival Data Reframes the Oncology Bet as Leadership Handover Looms

BioNTech's gotistobart showed 18.5-month median survival in squamous lung cancer at IASLC Seoul, as a 2027 CEO handover and vaccine revenue decline loom.

BioNTech used the global stage in Seoul this month to deliver the kind of clinical evidence that has been missing from its oncology narrative. At the IASLC World Conference on Lung Cancer, held from September 12 to 15, the Mainz-based company and its partner OncoC4 unveiled overall survival data from the Phase 3 PRESERVE-003 trial of gotistobart, an antibody targeting squamous non-small cell lung cancer in patients whose disease had progressed after prior therapies.

The numbers carry weight. Patients with advanced, metastatic squamous lung carcinoma survived a median of 18.5 months on gotistobart, compared with 10.0 months under standard chemotherapy. This is a population that had already seen its disease advance through immunotherapy and chemotherapy — among the hardest groups to treat. In oncology, that gap between arms is the raw material of genuine hope.

The Seoul presentations extended beyond gotistobart. BioNTech also released first global data on pumitamig combined with the antibody-drug conjugate elfetabart drozuntecan in small-cell and non-small-cell lung cancer. The pattern is deliberate: test multiple mechanisms at once, betting that at least one becomes the next blockbuster.

A Leadership Transition With an Unusually Long Runway

Running parallel to the clinical story is a governance shift that has been in motion since early August, when BioNTech announced that Guido Oelkers will take over as CEO on February 1, 2027. Founders Ugur Sahin and Özlem Türeci are set to depart by the end of 2026 to launch a separate company of their own.

For a business whose identity has been fused with its founding couple since inception, this marks a genuine rupture — softened, however, by an 18-month handover that is unusually gentle by industry standards.

One footnote deserves attention even if it says little on its own: Sahin sold shares on September 3 under a pre-arranged Rule 10b5-1 trading plan. Such automated programs are typically set months in advance and reveal nothing about management's view of the stock. Still, the timing lands just as the succession story gains definition.

The Share Price Moves to the Rhythm of Expectations

The market's response has been mixed. On Monday the stock added 2.4% to close at EUR 85.65, a move that lines up with the positive lung cancer data. In Tuesday trading it was up 2.9% at EUR 86.10.

Over the past month the shares have gained 8.2%, while the 12-month advance amounts to a modest 2.9%. The stock sits roughly 19% below its 52-week high of EUR 105.80 set in January, and about a quarter above its March low of EUR 68.35.

That spread tells the year's real story: a share caught between two narratives. On one side, shrinking vaccine revenue forced BioNTech in August to cut its annual guidance. On the other, an oncology pipeline generating excitement with data like Seoul's — but whose commercial proof will arrive in years, not quarters.

Analyst opinion has sorted itself precisely along this fault line. In early September, BMO Capital lowered its price target and downgraded the stock, citing faster-than-expected erosion of the Comirnaty business and the absence of "de-risking" data on pumitamig before 2028. On September 8, BMO cut its rating from "Outperform" to "Market Perform" and trimmed its target from USD 128 to USD 105. Late in August, Canaccord also reduced its target slightly while keeping a Buy rating.

The divergence in views mirrors the wager facing investors: does the oncology future outweigh the present reality of declining vaccine revenue?

A Setback That Sharpened the Focus

The Seoul data arrives on the heels of a significant blow in mRNA cancer vaccines. On August 29, BioNTech disclosed the termination of a Phase 2 trial of the experimental candidate autogene cevumeran. An independent monitoring committee had concluded the treatment was unlikely to extend survival in colorectal cancer patients. According to Reuters, the shares fell 7.5% on the US exchange after the news.

That development pushed analysts toward more cautious language and, for a time, pulled attention back to the antibody and combination programs now commanding the spotlight in Seoul.

On November 3, when BioNTech reports third-quarter results, the market will get a read on how durable the reduced revenue guidance of EUR 1.6 billion to EUR 1.9 billion really is. Until then, the stock remains what it has been all year: a test of how much patience the market will extend to a pharmaceutical company mid-rebuild.